医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Bonamour Receives CFS Certification from the Personal Care Products Council for Export Registration for Singapore and Vietnam Markets

2013年12月18日 PM11:25
このエントリーをはてなブックマークに追加


 

DALLAS

Bonamour, Inc., (OTCQB: BONI) announced today that the Company has received its Certificate of Free Sale issued by the Personal Care Products Counsel confirming that Bonamour products comply with all applicable state and federal guidelines in the United States of America. This certification is required by many Asian and European countries to facilitate the approval process for export of Bonamour products to such countries.

Bonamour, Inc. products are manufactured in compliance with all local and state laws and regulations and the Federal Food, Drug and Cosmetic Act, and, Bonamour, Inc. products are permitted to be sold in interstate commerce throughout the United States. In the United States, such skin care products are legally classified as cosmetics, and the U.S. Food and Drug Administration (FDA) has not promulgated Good Manufacturing Practice regulations (GMP’s) for cosmetics. However, the Personal Care Products Council (formerly CTFA) has issued Technical Guidelines in the areas of quality assurance, microbiology, and pharmacology/toxicology, as guidance documents in lieu of formal cosmetic GMPs in keeping with the U.S. cosmetic industry’s commitment in the area of self-regulation.

“We enjoyed great success during the test launch of these products in Hong Kong selling over 4,000 sets of our Bonamour Rejuvenating Trio in the limited trial period. We are working diligently to open markets in Singapore and Vietnam as these countries have very similar consumer demographics to Hong Kong.” said Nathan Halsey, CEO of Bonamour, Inc.

About Bonamour, Inc.:

Bonamour, Inc. is a Dallas-based developer and brand owner of a high end line of anti-aging skin care products often referred to as cosmeceuticals. The Company’s products are marketed and sold through its affiliate and sales arm, Bonamour International, LLC. Bonamour International is focused on building a network marketing and direct sales/distribution organization for the Bonamour brand in Asia. The Company’s target markets are comprised of nearly three billion people, many of whom are experiencing rapidly rising personal incomes and a strong affinity for U.S. made luxury goods. For additional information log on to www.bonamour.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, initiatives, goals, strategies and new product introductions; statements of projections regarding international sales targets and goals in Asia including Mainland China; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “project,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

— any changes in operations or future financial results from those currently anticipated;

— any failure of current or planned initiatives or products to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis;

— risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, including possible ingredient supply limitations;

— risk of foreign currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

— regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit the company’s ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;

— any inability to secure necessary governmental approvals or licenses to effect any future changes or expansion;

— regulatory scrutiny and investigations in target markets in Asia and other foreign markets, that could in the future, negatively impact the company’s business, including the interruption of sales activities in stores, loss of licenses, and the imposition of fines;

— adverse publicity related to the company’s business, products, industry or any legal actions or complaints by distributors or others; and

— continued competitive pressures in the company’s markets.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

CONTACT

Taylor Capital, Inc.
Stephen Taylor, 973-351-3868
STEPHTAYL9@AOL.COM

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent